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A B S T R A C T
Background: Certain patients with ﬂoppy mitral valve (FMV)/mitral valve prolapse (MVP) may have
symptoms that cannot be explained on the severity of mitral valvular regurgitation (MVR) alone;
hypersensitivity to adrenergic stimulation has been suggested in this group deﬁned as the FMV/MVP
syndrome.
Methods: Ninety-eight patients (75 men, 23 women) with mitral valve surgery for FMV/MVP were
studied. Of those 41 (42%) had symptoms consistent with FMV/MVP syndrome [29 men (39%), 12 women
(52%)]; median age of symptom onset was 30 years (range 10–63 years) and median duration of
symptoms prior to valve surgery was 16 years (range 3–50 years). Ninety-nine individuals (70 men, 29
women) without clinical evidence of any disease were used as controls. Genotyping of b1 and b2
adrenergic receptors was performed.
Results: b-Adrenergic receptor genotypes (b1 and b2) were similar between control and overall FMV/
MVP patients. Subgroup analysis of patients, however, demonstrated that the genotype C/C at position
1165 resulting in 389 Arg/Arg of the b1 receptor was more frequent in women compared to those without
FMV/MVP syndrome and to normal control women (p < 0.025). This polymorphism may be related to
hypersensitivity to adrenergic stimulation as reported previously in these patients.
Conclusion: This study shows a large proportion of patients with FMV/MVP, predominantly women, had
symptoms consistent with the FMV/MVP syndrome for many years prior to the development of
signiﬁcant MVR, and thus symptoms cannot be attributed to the severity of MVR alone. Further, women
with FMV/MVP syndrome, symptoms at least partially may be related to b1-adrenergic receptor
polymorphism, which has been shown previously to be associated with a hyperresponse to adrenergic
stimulation.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Certain patients with ﬂoppy mitral valve (FMV) associated with
mitral valve prolapse (MVP) may have symptoms that cannot be
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system functional abnormalities have been postulated as an
explanation for the symptoms in this group of patients, which is
classiﬁed as the FMV/MVP syndrome [1–14]. Many clinical
observations during the past 140 years suggested that individuals
with irritable heart, soldier’s heart, and neurocirculatory asthenia,
most likely related to FMV/MVP syndrome, had a disorder of the
sympathetic nervous system as a basis for their symptoms [15–17].
Previous studies from our laboratory demonstrated that patients
with the FMV/MVP syndrome, mostly females, had a high reserved.
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stimulation [9,10]. It is also known that certain polymorphisms
of b1-adrenergic receptors may result in an increased response to
adrenergic stimulation [18–22]. It was hypothesized that hyper-
sensitivity to adrenergic stimulation in certain patients with the
FMV/MVP syndrome is at least partially related to b-adrenergic
receptor polymorphism that results in hypersensitivity to b1-
adrenergic receptors. The present study was undertaken to test
this hypothesis.
Materials and methods
Study population
Demographic data are shown in Table 1. Ninety-eight patients
(75 men and 23 women) with a mean age of 57  13 years who had
mitral valve repair for severe MVR at St Lukas Hospital, Thessaloniki,
Greece, due to FMV/MVP from November 2008 to January 2011 were
studied. The mean systolic blood pressure was 135  10 mmHg and
the mean diastolic blood pressure was 80  5 mm Hg; the resting
heart rate was 76  14 beats per minute. The FMV/MVP and the
severity of MVR were established prior to surgery with two and three-
dimensional transthoracic and transesophageal echocardiogram;
FMV also was conﬁrmed in the operating room [23–31]. Mitral
leaﬂet prolapse was posterior in 53, anterior in 4, and bi-leaﬂet in 41
patients. Diffused thickening of the mitral valve was present in 40 and
regional thickening in 58 patients (Table 2). All patients had an apical
holosystolic murmur prior to surgery consistent with signiﬁcant
MVR. A detailed history, related to type, onset, and duration
of symptoms, especially of those symptoms consistent with the
FMV/MVP syndrome, was obtained [1–6,13]. Ninety-nine individualsTable 1
Demographic data of the study population.
Control (n = 99) FMV/MVP (n = 98)
Male 70 75
Female 29 23
Age 64  13 57  13
Systolic blood pressure 27  9 135  10
Diastolic blood pressure 82  6 85  5
FMV, ﬂoppy mitral valve; MVP, mitral valve prolapse.
Table 2
Clinical and echocardiographic data in patients with FMV/MVP (n = 98).
Male (n) 75
FMV/MVPS (n; %) 29 (38.6)
Female (n) 23
FMV/MVPS (n; %) 12 (52.2)
Leaﬂet prolapse (n)
Posterior 53
Anterior 4
Bi-leaﬂet 41
Chordae tendinae rupture (n) 46
Flail leaﬂet (n) 32
Diffuse thickening of MV (n) 40
Regional thickening of MV (n) 58
LVEDD (mm) 55  5
LA (mm) 46  6
LVEF (%) 61  9
RVSP (mmHg) 38  13
4+ severity of MVR (n; %) 98 (100)
FMV/MVPS, ﬂoppy mitral valve/mitral valve prolapse syndrome; LA,
left atrium; LVDD, left ventricular end diastolic diameter; LVEF, left
ventricular ejection fraction; MV, mitral valve; MVR, mitral valve
regurgitation; RVSP, right ventricular systolic pressure. The incidence
of symptoms related to FMV/MVP syndrome were more common in
women compared to men, p < 0.05.(70 men and 29 women) with a median age of 63 years (range 31–80
years) without evidence of any disease were used as controls [26]. The
study was approved by the Institutional Review Board of St. Lukas
Hospital and written informed consent was obtained from all
participants.
Determination of b-adrenergic receptor polymorphisms
Genomic DNA was isolated from lymphocytes in whole blood
using a commercially available kit (Qiagen DNA Blood Isolation Kit,
Qiagen, Valencia, CA, USA). DNA samples were genotyped for two
b1-adrenergic receptors (ADRB1) including: 49 Ser/Gly [amino acid
substitution of serine for glycine at position 49 resulting in the
nucleotide substitution of adenine for guanine at position 145 (145
A/G), rs1801252]; and 389 Arg/Gly [amino acid substitution of
arginine for glycine at position 389 resulting in the nucleotide
substitution of cytosine for guanine at position 1165 (1165C/G),
rs1801253]. In addition, DNA samples were genotyped for two b2-
adrenergic receptors (ADRB2) including: 16 Gly/Arg [amino acid
substitution of glycine for arginine at position 16 resulting in the
nucleotide substitution of guanine for adenine at position 46 (46 G/
A), rs1042713]; and 27 Gln/Glu [amino acid substitution of
glutamine for glutamic acid at position 27 resulting in the
nucleotide substitution of cytosine for guanine at position 79
(79C/G), rs1042714]. Single-nucleotide polymorphisms (SNPs)
were determined by polymerase chain reaction (PCR) followed
by pyrosequencing using a PSQ HS96A SNP reagent kit according to
the manufacturer protocol (Biotage AB, Uppsala, Sweden) and
TaqMan allelic discrimination (Applied Biosystems, Foster City, CA,
USA). The PCR primers and probes for ADRB1 49 Ser/Gly and 389
Arg/Gly (IDs C___8898508_10 and C___8898494_10), and ADRB2 16
Gly/Arg and 27 Gln/Glu (IDs C___2084764_20 and C___2084765_20)
used in assays were purchased from Applied Biosystems (Applied
Biosystems); 5 mL reactions in a 384-well plate were prepared and
the assays were performed and analyzed according to the
manufacturer’s recommendations. The PCR and pyrosequencing
primers for above-mentioned SNPs have been previously reported.
Genotype accuracy was veriﬁed by genotyping 5–10% randomly
selected duplicate samples for each SNP on the alternate platform
[19,32].
Statistical analysis
Genotypes of b1 and b2-adrenergic receptors between the
control group and the FMV/MVP patients were compared using a
Chi-square or a Fisher exact test. Further, patients who had
symptoms consistent with the FMV/MVP syndrome were com-
pared with the control group and to those patients with FMV/MVP
who did not have symptoms. A p-value of <0.05 was considered to
be statistically signiﬁcant.
Results
Forty-one patients (42%) had symptoms consistent with the
FMV/MVP syndrome. Twenty-nine out of 75 men (39%) and 12 out
of 23 women (52%) had symptoms consistent with the FMV/MVP
syndrome (Table 2). The incidence of FMV/MVP syndrome was
higher in women compared to men (p < 0.05). Twenty-one out of
40 patients (52%) with diffuse thickening of the mitral valve and 19
out of 58 patients (33%) with regional thickening of the mitral
valve had symptoms consistent with the FMV/MVP syndrome. The
median age of symptom onset was at 30 years (range 10–63 years)
and the median duration of symptoms was 16 years (range 3–50
years). Symptoms with age of onset and duration are shown in
Table 3. Twenty-ﬁve of the patients had a history of palpitations
with a median age of onset at 20 years (range 10–55 years) and
Table 3
Floppy mitral valve/mitral valve prolapse syndrome.
Symptoms Age of onset
(median and range)
Duration in years
(median and range)
Palpitations, n = 25 20 (10–55) 16 (3–50)
Fatigue, n = 5 25 (12–30) 16 (10–34)
Orthostatic phenomena,
n = 5 (syncope/presyncope)
35 (16–63) 7 (3–36)
Fig. 1. Frequency of genotype C/C at position 1165 (389 Arg/Arg) in patients with
FMV/MVP and in normal control subjects. FMV/MVP, ﬂoppy mitral valve/mitral
valve prolapse.
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palpitations due to atrial ﬁbrillation. Fatigue and exercise
intolerance were present in 5 patients with a median age of onset
at 25 years (range 12–30 years) and median duration of 16 years
(range 10–34 years). Orthostatic phenomena associated with
syncope or presyncope were seen in 5 patients with a median age
of onset at 35 years (range 16–63 years) and median duration of 7
years (range 3–36 years). Three patients had dyspnea with age
onset at 42, 44, and 47 years, and duration of 3, 4, and 10 years.
Chest pain was present in 2 patients in which 1 patient’s chest pain
started at the age of 40 years and underwent mitral valve surgery
at the age of 70 years; the other patient’s chest pain started at the
age of 50 years and underwent mitral valve surgery at the age of 71
years. One patient had frequent episodes of headaches that started
at the age of 40 years and underwent mitral valve surgery at the
age of 58 years. The duration of symptoms consistent with FMV/
MVP syndrome in all patients was long and occurred many years
prior to surgery, and thus symptoms cannot be attributed to the
severity of MVR alone. Indications for surgery were based solely on
the severity and symptoms related to mitral valve regurgitation.
There was no relationship between symptoms or duration of
symptoms due to FMV/MVP syndrome and surgery. After surgery
none of the patients reported dyspnea, orthostatic phenomena, or
fatigue; most of the patients (20 from 25) continued to have
palpitations. The follow-up interval, however, was relatively short
(1–4 years).
Frequencies of the b-adrenergic receptor genotypes (b1-
receptor and b2-receptor) in the Greek population with and with
FMV/MVP are shown in Table 4.
b-Adrenergic receptor genotypes were similar between control
and overall FMV/MVP patients. b1-Adrenergic receptor homozy-
gous genotype C/C at position 1165 resulting in 389 Arg/Arg in
control and FMV/MVP patients is shown in Fig. 1.
Sub-group analysis of females demonstrated that from the 23
females with FMV/MVP, 12 had symptoms consistent with FMV/
MVP syndrome in which 10 of these females (83%) had the
genotype C/C at position 1165. In the 11 of the 23 females with
FMV/MVP that did not have symptoms related to FMV/MVP
syndrome, only 5 of these females (46%) had the genotype C/C atTable 4
b-Adrenergic receptor genotypes in the Greek population.
Gene Receptor Nucleotide Am
ADRB1 b1-AR 1165 (C/C) 389
1165 (C/G) 389
1165 (G/G) 389
ADRB1 b1-AR 145 (A/A) 49
145 (A/G) 49
145 (G/G) 49
ADRB2 b2-AR 46 (G/G) 16
46 (G/A) 16
46 (A/A) 16
ADRB2 b2-AR 79 (C/C) 27
79 (C/G) 27
79 (G/G) 27
ADRB1, adrenergic receptor b1; b1-AR, b1 adrenergic receptor; ADRB2, adrenergic re
T, thymine; Arg, arginine; Glu, glutamic acid; Gln, glutamine; Gly, glycine; Ser, serinposition 1165. In normal control females, 14 out of 29 (48%) had
the genotype C/C at position 1165 (p = 0.025 among group; Fig. 2,
Table 5); this difference was not apparent in males.
There were no other differences found in the remaining b1-
receptor and b2-receptor genotypes between patients with
symptoms consistent with FMV/MVP syndrome and patients with
FMV/MVP without symptoms related to the FMV/MVP syndrome.
Discussion
Preliminary data for the type and natural history of FMV/MVP
syndrome symptoms were reported previously from our
laboratory [33].
The present study has shown that in certain patients with the
FMV/MVP syndrome, especially females, b-adrenergic receptor
polymorphisms may play a role in the pathogenesis of symptoms.
It also has shown that a large proportion of patients with FMV/MVP
have symptoms for years prior to the development of signiﬁcant
MVR and thus, cannot be explained on the basis of MVR alone.
MVP results from the systolic movement of portion(s) or
segments of the mitral valve leaﬂets into the left atrium during left
ventricular systole [13,34]. It is well-recognized today that FMV is
the central issue in the MVP/MVR story. The term FMV comes from
surgical and pathologic studies and refers to the expansion of the
area of the mitral valve leaﬂets with elongated chordae tendinae,ino acid Control (n = 99) FMV/MVP (n = 98)
Frequency (%) Frequency (%)
 (Arg/Arg) 48 51
 (Arg/Gly) 41 42
 (Gly/Gly) 10 5
 (Ser/Ser) 80 81
 (Ser/Gly) 16 17
 (Gly/Gly) 3 0
 (Gly/Gly) 39 28
 (Gly/Arg) 48 54
 (Arg/Arg) 12 16
 (Gln/Gln) 44 50
 (Gln/Glu) 47 36
 (Glu/Glu) 8 12
ceptor b2; b2-AR, b2 adrenergic receptor; A, adenine; C, cytosine; G, guanine;
e; FMV/MVP, ﬂoppy mitral valve/mitral valve prolapse.
Fig. 2. Frequency of genotype C/C at position 1165 (389 Arg/Arg) in female patients
with FMV/MVP with and without symptoms consistent with FMV/MVP syndrome.
Frequency of the same genotype in the normal control females is also shown. FMV/
MVP, ﬂoppy mitral valve/mitral valve prolapse.
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prevalence of FMV/MVP in the general population is 2–3%
[1,11,13,29,35]. FMV consists of a heritable heterogeneous group
with at least two forms of inheritance. One form is transmitted by
an autosomal dominant inheritance with a variable degree of
penetration; this is the most common type. At present three gene
loci have been reported. There is another less common form that is
transmitted through chromosome X [36].
If one accepts the hypothesis that some of the patients with the
FMV/MVP syndrome were previously considered to have an
irritable heart, soldier’s heart, or neurocirculatory asthenia, then
physicians have attempted to provide an explanation for these
symptoms for more than a century [15–17]. In all these earlier
observations, metabolic abnormalities, autonomic dysfunction,
and hyperresponse to adrenergic stimulation were considered as a
possible explanation for the symptoms of the FMV/MVP syndrome.
Fraser and Wilson [17], working in the Heart Section at a military
hospital in England during World War I, demonstrated that very
small doses of intravenous adrenaline produced a greater heart
rate and blood pressure response in soldiers with an ‘‘irritable
heart’’ compared to control subjects; they concluded that the
sympathetic nervous system was unstable in the irritable heart
soldiers. Peabody and his colleagues [16] at the United States Army
Hospital, New Jersey, studied the effect of intramuscular injectionsTable 5
Frequency (%) of b-adrenergic receptor genotypes in the patients with FMV/MVP synd
Gene Receptor Nucleotide Amino acid M-C
ADRB1 b1-AR 1165 (C/C) 389 (Arg/Arg) 49 
1165 (C/G) 389 (Arg/Gly) 44 
1165 (G/G) 389 (Gly/Gly) 7 
ADRB1 b1-AR 145 (A/A) 49 (Ser/Ser) 80 
145 (A/G) 49 (Ser/Gly) 17 
145 (G/G) 49 (Gly/Gly) 3 
ADRB1, adrenergic receptor b1; b1-AR, b1 adrenergic receptor; A, adenine; C, cytosine;
mitral valve prolapse; M-C, male control; M-Sx, male with symptoms consistent wit
syndrome; F-C, female control; F-Sx, female with symptoms consistent with FMV/MVP 
389 (Arg/Arg) genotype was more common in women with symptoms consistent wiof epinephrine in soldiers with irritable heart and compared the
results to a control group; they also demonstrated a hyperresponse
to epinephrine and concluded that ‘‘it is distinctly interesting
therefore that so large a proportion should be hypersensitive to
epinephrine, and one should at least consider carefully whether an
unusually excitable sympathetic nervous system may play a part in
determining their condition.’’ Boudoulas et al. [10] demonstrated
that symptomatic patients with the FMV/MVP syndrome, mostly
females, with high adrenergic tone at rest had hypersensitivity to
isoproterenol administration as manifested by dose-related repro-
duction of symptoms and greater heart rate response compared to
control subjects. Increased 24-h urinary epinephrine and norepi-
nephrine excretion, and high plasma catecholamines in symptom-
atic patients with MVP syndrome have been reported from our
group and others [4,5,9,12]. The present study extends previous
observations and provides insight into the pathophysiologic
mechanisms related to hypersensitivity to adrenergic stimulation
in patients with the FMV/MVP syndrome. Indeed the frequency of
the homozygous genotype C/C at position 1165 resulting in 389 Arg/
Arg was more frequent in women who had symptoms consistent
with the FMV/MVP syndrome [18–22,37]. This polymorphism may
be related to a hyperresponse to adrenergic stimulation as reported
previously [10]. High adrenergic activity in FMV/MVP further
increases when signiﬁcant MVR occurs and may have signiﬁcant
implications in myocardial function [38,39].
In addition to high adrenergic activity, there are several other
mechanisms that may be related to the pathogenesis of symptoms in
patients with the FMV/MVP syndrome including the development of
the third chamber, papillary muscle traction, and mitral valve nerve
ending stimulation. The third chamber is developed during left
ventricular systole within the border of the mitral valve annulus and
the prolapsing mitral valve leaﬂets. Thus, during left ventricular
systole the heart consists of three chambers (left ventricle, left
atrium, and the third chamber) [6,13]. The third chamber acts like a
left ventricular aneurysm since blood within the space of the third
chamber does not contribute to the effective stroke volume. The
degree of prolapse increases in the upright position, which may
further decrease the effective stroke volume and forward cardiac
output contributing to the orthostatic phenomena [7,40]. Prolapsing
mitral valve results in traction of the papillary muscles that may
produce chest pain and activation of stretch receptors leading to
membrane depolarization and cardiac arrhythmias [41–45]. Me-
chanical stimuli due to abnormal coaptation of the FMV/MVP may
cause an abnormal autonomic nerve feedback between the central
nervous system and the mitral valve [1,13].
This study shows that patients with FMV/MVP who developed
signiﬁcant MVR requiring surgery had symptoms for several years
prior to surgery that were not directly related to the severity of
MVR. Symptoms in patients with MVP without signiﬁcant MVR
(i.e. MVP syndrome) have been reported previously from numer-
ous investigators [4,5,9,10,12,33]. However, in most of these
previous studies symptoms were reported at one particular timerome (n = 98) and in the control group.
 M-Sx M-No Sx F-C F-Sx F-No Sx
52 50 48 83 46
48 41 35 17 45
0 9 17 0 9
76 85 86 83 82
24 15 10 8.5 18
0 0 4 8.5 0
 G, guanine; Arg, arginine; Gly, glycine; Ser, serine; FMV/MVP, ﬂoppy mitral valve/
h FMV/MVP syndrome; M-No Sx, male with no symptoms related to FMV/MVP
syndrome; F-No Sx, female with no symptoms related to FMV/MVP syndrome. The
th FMV/MVP syndrome compared to other groups, p = 0.025.
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symptoms was not deﬁned. In this study, symptoms were analyzed
from their onset until surgery. In this group of patients, the
incidence of the FMV/MVP syndrome was high and the duration of
symptoms was exceptionally long. Further, in most previous
studies the diagnosis of MVP was mostly based on echocardio-
graphic criteria (M-mode or 2-dimensional) of mitral valve
prolapse without deﬁning if the mitral valve was ﬂoppy. It should
be emphasized that MVP may be a non-speciﬁc ﬁnding since it also
depends on left ventricular contractility, left ventricular volume,
and other ventricular hemodynamics. In this study the diagnosis of
FMV was established with transesophageal two- and three-
dimensional echocardiography and also was conﬁrmed in the
operating room in all patients.
In conclusion, the results of this study have shown that a large
proportion of patients with FMV/MVP have symptoms consistent
with FMV/MVP syndrome for many years prior to the development
of signiﬁcant MVR and thus, cannot be attributed to MVR alone.
These symptoms were more prominent in women compared to
men. The diagnosis of FMV/MVP was established in all patients
with transesophageal two- and three-dimensional echocardiogra-
phy and it was conﬁrmed in all patients in the operating room. It
has also been shown that women with symptoms consistent with
the FMV/MVP syndrome may be partially related to b-adrenergic
receptor polymorphism that provides an explanation to the
hyperresponse to adrenergic stimulation.
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